A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Description

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions

Refractory Chronic Cough

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Condition
Refractory Chronic Cough
Intervention / Treatment

-

Contacts and Locations

Jasper

Jasper Summit Research, LLC, Jasper, Alabama, United States, 35501

Litchfield Park

Research Solutions of Arizona, PC, Litchfield Park, Arizona, United States, 85340

Scottsdale

Medical Research of Arizona, Scottsdale, Arizona, United States, 85248

Little Rock

Little Rock Allergy & Asthma, P.A. Clinical Research Center, Little Rock, Arkansas, United States, 72205

Encinitas

Warren W. Pleskow, MD, 1071572, Encinitas, California, United States, 92024

Mission Viejo

Allergy & Asthma Research of Southern California, Mission Viejo, California, United States, 92691

Paramount

Center for Clinical Trials, LLC, Paramount, California, United States, 90723

San Diego

Allergy Associates Medical Group, Inc., San Diego, California, United States, 92120

Aurora

Care Access Research, Aurora, Colorado, United States, 80012

Clearwater

Innovative Research of West Florida, Inc., Clearwater, Florida, United States, 33756

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Capable of giving signed informed consent
  • * Refractory chronic cough (including unexplained chronic cough) for at least one year
  • * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose
  • * Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
  • * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma
  • * Respiratory tract infection within 4 weeks before screening
  • * Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
  • * History of malignancy in the last 5 years
  • * History of alcohol or drug abuse within the last 3 years
  • * Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
  • * Previous participation in a BLU-5937 trial

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bellus Health Inc. - a GSK company,

Study Record Dates

2026-03